

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
30 August 2001 (30.08.2001)

PCT

(10) International Publication Number  
**WO 01/62940 A2**

(51) International Patent Classification<sup>7</sup>: **C12N 15/55**,  
15/10, 15/62, 9/16, C07K 16/40, C12Q 1/44, G01N 33/53,  
C12Q 1/68

**Franz-Werner** [DE/DE]; Bahnhofstrasse 39, 64367  
Mühlthal (DE). **HENTSCH, Bernd** [DE/DE]; Kaupstrasse  
48, 64289 Darmstadt (DE).

(21) International Application Number: PCT/EP01/01858

(74) Common Representative: **MERCK PATENT GMBH**;  
Frankfurter Strasse 250, 64293 Darmstadt (DE).

(22) International Filing Date: 20 February 2001 (20.02.2001)

(25) Filing Language: English

(81) Designated States (*national*): CA, JP, US.

(26) Publication Language: English

(84) Designated States (*regional*): European patent (AT, BE,  
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,  
NL, PT, SE, TR).

(30) Priority Data:  
00103655.7 21 February 2000 (21.02.2000) EP

**Published:**

— without international search report and to be republished  
upon receipt of that report

(71) Applicant (*for all designated States except US*): **MERCK  
PATENT GMBH** [DE/DE]; Frankfurter Strasse 250,  
64293 Darmstadt (DE).

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **KLUXEN**,



**WO 01/62940 A2**

(54) Title: NEW PHOSPHODIESTERASE TYPE 7B

(57) Abstract: Platelet-derived growth factor D polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing platelet-derived growth factor D polypeptides and polynucleotides in diagnostic assays.

## New phosphodiesterase type 7b

### Field of the Invention

5 This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides sometimes hereinafter referred to as „novel phosphodiesterase type 7b (PDE7b)“, to their use in diagnosis and in identifying compounds that may be agonists, antagonists that are potentially useful in therapy, and to production of such polypeptides and polynucleotides.

10

### Background of the Invention

The drug discovery process is currently undergoing a fundamental revolution as it embraces "functional genomics", that is, high throughput genome- or gene-based biology. This approach as a means to identify genes and gene products as therapeutic targets is rapidly superceding earlier approaches based on "positional cloning". A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.

15

20 Functional genomics relies heavily on high-throughput DNA sequencing technologies and the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.

25

### Summary of the Invention

30 The present invention relates to PDE7b, in particular PDE7b polypeptides and PDE7b polynucleotides, recombinant materials and methods for their production. Such polypeptides and polynucleotides are of interest in relation to methods of treatment of certain diseases correlated with aberrant

regulation of cyclic nucleotide levels. Such diseases including, but are not limited to, diseases like cardiovascular diseases, asthma, allergy, inflammatory diseases, some immunrelated disorders, hereinafter referred to as "diseases of the invention". In a further aspect, the invention relates to methods for identifying agonists and antagonists (e.g., inhibitors) using the materials provided by the invention, and treating conditions associated with PDE7b imbalance with the identified compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate PDE7b activity or levels.

### Description of the Invention

In a first aspect, the present invention relates to PDE7b polypeptides. Such polypeptides include:

(a) a polypeptide encoded by a polynucleotide comprising the sequence given in the SEQ ID NO: 1 OR 3;

(b) a polypeptide comprising a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence in the SEQ ID NO: 2 OR 4;

(c) a polypeptide comprising the polypeptide sequence given in the SEQ ID NO: 2 OR 4

(d) a polypeptide having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of the SEQ ID NO: 2 OR 4;

(e) the polypeptide sequence of the SEQ ID NO: 2 OR 4; and

(f) a polypeptide having or comprising a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to the polypeptide sequence given in the SEQ ID NO: 2 OR 4;

(g) fragments and variants of such polypeptides in (a) to (f).

Polypeptides of the present invention are believed to be members of the cAMP phosphodiesterases family of polypeptides. They are therefore of interest because the sequence encodes a variant of the cAMP phosphodiesterase type 7. Phosphodiesterases are involved in regulation of

the cellular levels of cAMP and thus play a vital role in a large number of physiological processes. Aberrant regulation of cyclic nucleotide levels have been implicated in many diseases like cardiovascular diseases, asthma, allergy, inflammatory diseases, some immunrelated disorders and many more.

5

The biological properties of the PDE7b are hereinafter referred to as "biological activity of PDE7b" or "PDE7b activity". Preferably, a polypeptide of the present invention exhibits at least one biological activity of PDE7b.

10

Polypeptides of the present invention also includes variants of the aforementioned polypeptides, including all allelic forms and splice variants. Such polypeptides vary from the reference polypeptide by insertions, deletions, and substitutions that may be conservative or non-conservative, or any combination thereof. Particularly preferred variants are those in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 15

10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acids are inserted, substituted, or deleted, in any combination.

15

Preferred fragments of polypeptides of the present invention include an isolated polypeptide comprising an amino acid sequence having at least 20

30, 50 or 100 contiguous amino acids from the amino acid sequence of the SEQ ID NO: 2 OR 4, or an isolated polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids truncated or deleted from the amino acid sequence of the SEQ ID NO: 2 OR 4. Preferred fragments are biologically active fragments that mediate the biological activity of PDE7b, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also preferred are those fragments that are antigenic or immunogenic in an animal, especially in a human.

20

25

Fragments of the polypeptides of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these variants may be employed as intermediates for producing the full-length polypeptides of the invention. The polypeptides of the present invention may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence that

30

35

contains secretory or leader sequences, pro-sequences, sequences that aid in purification, for instance multiple histidine residues, or an additional sequence for stability during recombinant production.

5 Polypeptides of the present invention can be prepared in any suitable manner, for instance by isolation from naturally occurring sources, from genetically engineered host cells comprising expression systems (*vide infra*) or by chemical synthesis, using for instance automated peptide synthesisers, or a combination of such methods.. Means for preparing such polypeptides are well understood in the art.

10

In a further aspect, the present invention relates to PDE7b polynucleotides. Such polynucleotides include:

(a) a polynucleotide comprising a polynucleotide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polynucleotide sequence of the SEQ ID NO: 1 OR 3;

15

(b) a polynucleotide comprising the polynucleotide of the SEQ ID NO: 1 OR 3;

(c) a polynucleotide having at least 95%, 96%, 97%, 98%, or 99% identity to the polynucleotide of the SEQ ID NO: 1 OR 3;

20

(d) the polynucleotide of the SEQ ID NO: 1 OR 3;

(e) a polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of the SEQ ID NO: 2 OR 4;

25

(f) a polynucleotide comprising a polynucleotide sequence encoding the polypeptide of the SEQ ID NO: 2 OR 4;

(g) a polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of the SEQ ID NO: 2 OR 4;

(h) a polynucleotide encoding the polypeptide of the SEQ ID NO: 2 OR 4;

(i) a polynucleotide having or comprising a polynucleotide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to the polynucleotide sequence of the SEQ ID NO: 1 OR 3 ;

5 (j) a polynucleotide having or comprising a polynucleotide sequence encoding a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to the polypeptide sequence of the SEQ ID NO: 2 OR 4; and polynucleotides that are fragments and variants of the above mentioned polynucleotides or that are complementary to above mentioned polynucleotides, over the entire length thereof.

10 Preferred fragments of polynucleotides of the present invention include a polynucleotide comprising an nucleotide sequence having at least 15, 30, 50 or 100 contiguous nucleotides from the sequence of the SEQ ID NO: 1 OR 3 or an isolated polynucleotide comprising an sequence having at least 30, 50 or 100 contiguous nucleotides truncated or deleted from the  
15 sequence of the SEQ ID NO: 1 OR 3.

Preferred variants of polynucleotides of the present invention include splice variants, allelic variants, and polymorphisms, including polynucleotides having one or more single nucleotide polymorphisms (SNPs).

20 Polynucleotides of the present invention also include polynucleotides encoding polypeptide variants that comprise the amino acid sequence of the SEQ ID NO: 2 OR 4 and in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acid residues are substituted, deleted or added, in any  
25 combination.

In a further aspect, the present invention provides polynucleotides that are RNA transcripts of the DNA sequences of the present invention. Accordingly, there is provided an RNA polynucleotide that:

30 (a) comprises an RNA transcript of the DNA sequence encoding the polypeptide of the SEQ ID NO: 2 OR 4;

(b) is the RNA transcript of the DNA sequence encoding the polypeptide of the SEQ ID NO: 2 OR 4;

(c) comprises an RNA transcript of the DNA sequence of the SEQ ID NO: 1 OR 3; or

(d) is the RNA transcript of the DNA sequence of the SEQ ID NO: 1 OR 3;

5 and RNA polynucleotides that are complementary thereto.

The polynucleotide sequence of the SEQ ID NO: 1 OR 3 shows homology with homo sapiens cAMP phosphodiesterase PDE7 (PDE7A2) (Han, P. et al., J. Biol. Chem. 272 (26), 16152-16157 (1997). The polynucleotide  
10 sequence of the SEQ ID NO: 1 OR 3 is a cDNA sequence that encodes the polypeptide of the SEQ ID NO: 2 OR 4. The polynucleotide sequence encoding the polypeptide of the SEQ ID NO: 2 OR 4 may be identical to the polypeptide encoding sequence of the SEQ ID NO: 2 OR 4 or it may be a sequence other than SEQ ID NO: 2 OR 4, which, as a result of the  
15 redundancy (degeneracy) of the genetic code, also encodes the polypeptide of the SEQ ID NO: 2 OR 4. The polypeptide of the SEQ ID NO: 2 OR 4 is related to other proteins of the cAMP phosphodiesterases family, having homology and/or structural similarity with **Fehler! Unbekanntes Schalterargument.**

20 Preferred polypeptides and polynucleotides of the present invention are expected to have, *inter alia*, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one PDE7b activity.

25 Polynucleotides of the present invention may be obtained using standard cloning and screening techniques from a cDNA library derived from mRNA in cells of the brain, kidney, endothelial cells see for instance, Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)). Polynucleotides of  
30 the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

When polynucleotides of the present invention are used for the recombinant production of polypeptides of the present invention, the polynucleotide may include the coding sequence for the mature polypeptide, by itself, or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gents *et al.*, Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

Polynucleotides that are identical, or have sufficient identity to a polynucleotide sequence of the SEQ ID NO: 1 OR 3, may be used as hybridization probes for cDNA and genomic DNA or as primers for a nucleic acid amplification reaction (for instance, PCR). Such probes and primers may be used to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic clones of other genes (including genes encoding paralogs from human sources and orthologs and paralogs from species other than human) that have a high sequence similarity to the SEQ ID NO: 1 OR 3, typically at least 95% identity. Preferred probes and primers will generally comprise at least 15 nucleotides, preferably, at least 30 nucleotides and may have at least 50, if not at least 100 nucleotides. Particularly preferred probes will have between 30 and 50 nucleotides. Particularly preferred primers will have between 20 and 25 nucleotides.

A polynucleotide encoding a polypeptide of the present invention, including homologs from species other than human, may be obtained by a process comprising the steps of screening a library under stringent hybridization conditions with a labeled probe having the sequence of the SEQ ID NO: 1 OR 3 or a fragment thereof, preferably of at least 15 nucleotides; and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Such hybridization techniques are well known to the skilled artisan. Preferred stringent hybridization conditions include

overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA; followed by washing the filters in  
5 0.1x SSC at about 65°C. Thus the present invention also includes isolated polynucleotides, preferably with a nucleotide sequence of at least 100, obtained by screening a library under stringent hybridization conditions with a labeled probe having the sequence of the SEQ ID NO: 1 OR 3 or a fragment thereof, preferably of at least 15 nucleotides.

10 The skilled artisan will appreciate that, in many cases, an isolated cDNA sequence will be incomplete, in that the region coding for the polypeptide does not extend all the way through to the 5' terminus. This is a consequence of reverse transcriptase, an enzyme with inherently low "processivity" (a measure of the ability of the enzyme to remain attached  
15 to the template during the polymerisation reaction), failing to complete a DNA copy of the mRNA template during first strand cDNA synthesis.

There are several methods available and well known to those skilled in the art to obtain full-length cDNAs, or extend short cDNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE)  
20 (see, for example, Frohman et al., Proc Nat Acad Sci USA 85, 8998-9002, 1988). Recent modifications of the technique, exemplified by the Marathon (trade mark) technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon (trade mark) technology, cDNAs have been prepared from  
25 mRNA extracted from a chosen tissue and an 'adaptor' sequence ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the "missing" 5' end of the cDNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using 'nested' primers, that is, primers designed to  
30 anneal within the amplified product (typically an adaptor specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' in the known gene sequence). The products of this reaction can then be analysed by DNA sequencing and a full-length cDNA constructed either by joining the product directly to the  
35 existing cDNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.

Recombinant polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Accordingly, in a further aspect, the present invention relates to expression systems comprising a polynucleotide or polynucleotides of the present invention, to host cells which are genetically engineered with such expression systems and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Polynucleotides may be introduced into host cells by methods described in many standard laboratory manuals, such as Davis et al., *Basic Methods in Molecular Biology* (1986) and Sambrook *et al. (ibid)*. Preferred methods of introducing polynucleotides into host cells include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as *Streptococci*, *Staphylococci*, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

A great variety of expression systems can be used, for instance, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as

cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any system or vector that is able to maintain, propagate or express a polynucleotide to produce a polypeptide in a host may be used. The appropriate polynucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, (*ibid*). Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.

If a polypeptide of the present invention is to be expressed for use in screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during intracellular synthesis, isolation and/or purification.

Polynucleotides of the present invention may be used as diagnostic reagents, through detecting mutations in the associated gene. Detection of a mutated form of the gene characterised by the polynucleotide of the SEQ ID NO: 1 OR 3 in the cDNA or genomic sequence and which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered spatial or temporal expression

of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques well known in the art.

5 Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or it may be amplified enzymatically by using PCR, preferably RT-PCR, or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by  
10 hybridizing amplified DNA to labeled PDE7b nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence difference may also be detected by alterations in the electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (see, for instance, Myers  
15 *et al.*, Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, Proc Natl Acad Sci USA (1985) 85: 4397-4401).

20 An array of oligonucleotide probes comprising PDE7b polynucleotide sequence or fragments thereof can be constructed to conduct efficient screening of *e.g.*, genetic mutations. Such arrays are preferably high density arrays or grids. Array technology methods are well known and have general applicability and can be used to address a variety of  
25 questions in molecular genetics including gene expression, genetic linkage, and genetic variability, see, for example, M.Chee *et al.*, Science, 274, 610-613 (1996) and other references cited therein.

Detection of abnormally decreased or increased levels of polypeptide or mRNA expression may also be used for diagnosing or determining  
30 susceptibility of a subject to a disease of the invention. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization  
35 methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample derived

from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

Thus in another aspect, the present invention relates to a diagnostic kit comprising:

(a) a polynucleotide of the present invention, preferably the nucleotide sequence of the SEQ ID NO: 1 OR 3, or a fragment or an RNA transcript thereof;

(b) a nucleotide sequence complementary to that of (a);

(c) a polypeptide of the present invention, preferably the polypeptide of the SEQ ID NO: 2 OR 4; or

(d) an antibody to a polypeptide of the present invention, preferably to the polypeptide of the SEQ ID NO: 2 OR 4.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly diseases of the invention, amongst others.

The polynucleotide sequences of the present invention are valuable for chromosome localisation studies. The sequence is specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (co-inheritance of physically adjacent genes). Precise human chromosomal localisations for a genomic sequence (gene fragment etc.) can be determined using Radiation Hybrid (RH) Mapping

(Walter, M. Spillett, D., Thomas, P., Weissenbach, J., and Goodfellow, P., (1994) A method for constructing radiation hybrid maps of whole genomes, *Nature Genetics* 7, 22-28). A number of RH panels are available from Research Genetics (Huntsville, AL, USA) e.g. the GeneBridge4 RH panel (*Hum Mol Genet* 1996 Mar;5(3):339-46 A radiation hybrid map of the human genome. Gyapay G, Schmitt K, Fizames C, Jones H, Vega-Czarny N, Spillett D, Muselet D, Prud'Homme JF, Dib C, Auffray C, Morissette J, Weissenbach J, Goodfellow PN). To determine the chromosomal location of a gene using this panel, 93 PCRs are performed using primers designed from the gene of interest on RH DNAs. Each of these DNAs contains random human genomic fragments maintained in a hamster background (human / hamster hybrid cell lines). These PCRs result in 93 scores indicating the presence or absence of the PCR product of the gene of interest. These scores are compared with scores created using PCR products from genomic sequences of known location. This comparison is conducted at <http://www.genome.wi.mit.edu/>. The gene of the present invention maps to human chromosome 6.

The polynucleotide sequences of the present invention are also valuable tools for tissue expression studies. Such studies allow the determination of expression patterns of polynucleotides of the present invention which may give an indication as to the expression patterns of the encoded polypeptides in tissues, by detecting the mRNAs that encode them. The techniques used are well known in the art and include in situ hybridisation techniques to clones arrayed on a grid, such as cDNA microarray hybridisation (Schena *et al*, *Science*, 270, 467-470, 1995 and Shalon *et al*, *Genome Res*, 6, 639-645, 1996) and nucleotide amplification techniques such as PCR. A preferred method uses the TAQMAN (Trade mark) technology available from Perkin Elmer. Results from these studies can provide an indication of the normal function of the polypeptide in the organism. In addition, comparative studies of the normal expression pattern of mRNAs with that of mRNAs encoded by an alternative form of the same gene (for example, one having an alteration in polypeptide coding potential or a regulatory mutation) can provide valuable insights into the role of the polypeptides of the present invention, or that of inappropriate

expression thereof in disease. Such inappropriate expression may be of a temporal, spatial or simply quantitative nature.

The polypeptides of the present invention are expressed in **Fehler! Unbekanntes Schalterargument.**

5

A further aspect of the present invention relates to antibodies. The polypeptides of the invention or their fragments, or cells expressing them, can be used as immunogens to produce antibodies that are immunospecific for polypeptides of the present invention. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

10

15

20

Antibodies generated against polypeptides of the present invention may be obtained by administering the polypeptides or epitope-bearing fragments, or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., Nature (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, Immunology Today (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, Monoclonal Antibodies and Cancer Therapy, 77-96, Alan R. Liss, Inc., 1985).

25

Techniques for the production of single chain antibodies, such as those described in U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.

30

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography. Antibodies against polypeptides of the present invention may also be employed to treat diseases of the invention, amongst others.

Polypeptides and polynucleotides of the present invention may also be used as vaccines. Accordingly, in a further aspect, the present invention relates to a method for inducing an immunological response in a mammal that comprises inoculating the mammal with a polypeptide of the present invention, adequate to produce antibody and/or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said animal from disease, whether that disease is already established within the individual or not. An immunological response in a mammal may also be induced by a method comprises delivering a polypeptide of the present invention *via* a vector directing expression of the polynucleotide and coding for the polypeptide *in vivo* in order to induce such an immunological response to produce antibody to protect said animal from diseases of the invention. One way of administering the vector is by accelerating it into the desired cells as a coating on particles or otherwise. Such nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or a DNA/RNA hybrid. For use a vaccine, a polypeptide or a nucleic acid vector will be normally provided as a vaccine formulation (composition). The formulation may further comprise a suitable carrier. Since a polypeptide may be broken down in the stomach, it is preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions that may contain anti-oxidants, buffers, bacteriostats and solutes that render the formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions that may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

35

Polypeptides of the present invention have one or more biological functions that are of relevance in one or more disease states, in particular the

diseases of the invention hereinbefore mentioned. It is therefore useful to to identify compounds that stimulate or inhibit the function or level of the polypeptide. Accordingly, in a further aspect, the present invention provides for a method of screening compounds to identify those that stimulate or inhibit the function or level of the polypeptide. Such methods identify agonists or antagonists that may be employed for therapeutic and prophylactic purposes for such diseases of the invention as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, collections of chemical compounds, and natural product mixtures. Such agonists or antagonists so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the polypeptide; a structural or functional mimetic thereof (see Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991)) or a small molecule.

The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof, by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve measuring or detecting (qualitatively or quantitatively) the competitive binding of a candidate compound to the polypeptide against a labeled competitor (*e.g.* agonist or antagonist). Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring a PDE7b activity in the mixture, and comparing the PDE7b activity of the mixture to a control mixture which contains no candidate compound.

Polypeptides of the present invention may be employed in conventional low capacity screening methods and also in high-throughput screening (HTS) formats. Such HTS formats include not only the well-established use of 96- and, more recently, 384-well micotiter plates but also emerging

methods such as the nanowell method described by Schullek et al, Anal Biochem., 246, 20-29, (1997).

Fusion proteins, such as those made from Fc portion and PDE7b polypeptide, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists for the polypeptide of the present invention (see D. Bennett *et al.*, J Mol Recognition, 8:52-58 (1995); and K. Johanson *et al.*, J Biol Chem, 270(16):9459-9471 (1995)).

#### 10 Screening techniques

The polynucleotides, polypeptides and antibodies to the polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents that may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

A polypeptide of the present invention may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance,  $^{125}\text{I}$ ), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists and antagonists of the polypeptide that compete with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.

Examples of antagonists of polypeptides of the present invention include antibodies or, in some cases, oligonucleotides or proteins that are closely related to the ligands, substrates, receptors, enzymes, etc., as the case may be, of the polypeptide, e.g., a fragment of the ligands, substrates, receptors, enzymes, etc.; or a small molecule that bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.

Screening methods may also involve the use of transgenic technology and PDE7b gene. The art of constructing transgenic animals is well established. For example, the PDE7b gene may be introduced through microinjection into the male pronucleus of fertilized oocytes, retroviral transfer into pre- or post-implantation embryos, or injection of genetically modified, such as by electroporation, embryonic stem cells into host blastocysts. Particularly useful transgenic animals are so-called "knock-in" animals in which an animal gene is replaced by the human equivalent within the genome of that animal. Knock-in transgenic animals are useful in the drug discovery process, for target validation, where the compound is specific for the human target. Other useful transgenic animals are so-called "knock-out" animals in which the expression of the animal ortholog of a polypeptide of the present invention and encoded by an endogenous DNA sequence in a cell is partially or completely annulled. The gene knock-out may be targeted to specific cells or tissues, may occur only in certain cells or tissues as a consequence of the limitations of the technology, or may occur in all, or substantially all, cells in the animal. Transgenic animal technology also offers a whole animal expression-cloning system in which introduced genes are expressed to give large amounts of polypeptides of the present invention

Screening kits for use in the above described methods form a further aspect of the present invention. Such screening kits comprise:

- (a) a polypeptide of the present invention;
- (b) a recombinant cell expressing a polypeptide of the present invention;
- (c) a cell membrane expressing a polypeptide of the present invention; or
- (d) an antibody to a polypeptide of the present invention;

which polypeptide is preferably that of the SEQ ID NO: 2 OR 4.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

## 5           **Glossary**

The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

10           “Antibodies” as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an

Fab or other immunoglobulin expression library.

15           “Isolated” means altered “by the hand of man” from its natural state, *i.e.*, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living organism is not “isolated,” but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is “isolated”, as the term is employed herein. Moreover, a polynucleotide or polypeptide that is introduced into an organism by transformation, genetic manipulation or by any other recombinant method  
20           is “isolated” even if it is still present in said organism, which organism may be living or non-living.

25           “Polynucleotide” generally refers to any polyribonucleotide (RNA) or polydeoxribonucleotide (DNA), which may be unmodified or modified RNA or DNA. “Polynucleotides” include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In  
30           addition, “polynucleotide” refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term “polynucleotide” also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons.

“Modified” bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, “polynucleotide” embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. “Polynucleotide” also embraces relatively short polynucleotides, often referred to as oligonucleotides.

“Polypeptide” refers to any polypeptide comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. “Polypeptide” refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. “Polypeptides” include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques that are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications may occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, biotinylation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to

proteins such as arginylation, and ubiquitination (see, for instance, Proteins - Structure and Molecular Properties, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., Post-translational Protein Modifications: Perspectives and Prospects, 1-12, in Post-translational Covalent Modification of Proteins, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", Meth Enzymol, 182, 626-646, 1990, and Rattan *et al.*, "Protein Synthesis: Post-translational Modifications and Aging", Ann NY Acad Sci, 663, 48-62, 1992).

"Fragment" of a polypeptide sequence refers to a polypeptide sequence that is shorter than the reference sequence but that retains essentially the same biological function or activity as the reference polypeptide. "Fragment" of a polynucleotide sequence refers to a polynucleotide sequence that is shorter than the reference sequence of the SEQ ID NO: 1 OR 3.

"Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains the essential properties thereof. A typical variant of a polynucleotide differs in nucleotide sequence from the reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from the reference polypeptide. Generally, alterations are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, insertions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. Typical conservative substitutions include Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe and Tyr. A variant of a polynucleotide or polypeptide may be naturally occurring such as an allele, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis. Also included as variants

are polypeptides having one or more post-translational modifications, for instance glycosylation, phosphorylation, methylation, ADP ribosylation and the like. Embodiments include methylation of the N-terminal amino acid, phosphorylations of serines and threonines and modification of C-terminal glycines.

"Allele" refers to one of two or more alternative forms of a gene occurring at a given locus in the genome.

"Polymorphism" refers to a variation in nucleotide sequence (and encoded polypeptide sequence, if relevant) at a given position in the genome within a population.

"Single Nucleotide Polymorphism" (SNP) refers to the occurrence of nucleotide variability at a single nucleotide position in the genome, within a population. An SNP may occur within a gene or within intergenic regions of the genome. SNPs can be assayed using Allele Specific Amplification (ASA). For the process at least 3 primers are required. A common primer is used in reverse complement to the polymorphism being assayed. This common primer can be between 50 and 1500 bps from the polymorphic base. The other two (or more) primers are identical to each other except that the final 3' base wobbles to match one of the two (or more) alleles that make up the polymorphism. Two (or more) PCR reactions are then conducted on sample DNA, each using the common primer and one of the Allele Specific Primers.

"Splice Variant" as used herein refers to cDNA molecules produced from RNA molecules initially transcribed from the same genomic DNA sequence but which have undergone alternative RNA splicing. Alternative RNA splicing occurs when a primary RNA transcript undergoes splicing, generally for the removal of introns, which results in the production of more than one mRNA molecule each of that may encode different amino acid sequences. The term splice variant also refers to the proteins encoded by the above cDNA molecules.

"Identity" reflects a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, determined by comparing the sequences. In general, identity refers to an exact nucleotide to nucleotide or amino acid to amino acid correspondence of

the two polynucleotide or two polypeptide sequences, respectively, over the length of the sequences being compared.

"% Identity" - For sequences where there is not an exact correspondence, a "% identity" may be determined. In general, the two sequences to be compared are aligned to give a maximum correlation between the sequences. This may include inserting "gaps" in either one or both sequences, to enhance the degree of alignment. A % identity may be determined over the whole length of each of the sequences being compared (so-called global alignment), that is particularly suitable for sequences of the same or very similar length, or over shorter, defined lengths (so-called local alignment), that is more suitable for sequences of unequal length.

"Similarity" is a further, more sophisticated measure of the relationship between two polypeptide sequences. In general, "similarity" means a comparison between the amino acids of two polypeptide chains, on a residue by residue basis, taking into account not only exact correspondences between a between pairs of residues, one from each of the sequences being compared (as for identity) but also, where there is not an exact correspondence, whether, on an evolutionary basis, one residue is a likely substitute for the other. This likelihood has an associated "score" from which the "% similarity" of the two sequences can then be determined.

Methods for comparing the identity and similarity of two or more sequences are well known in the art. Thus for instance, programs available in the Wisconsin Sequence Analysis Package, version 9.1 (Devereux J et al, Nucleic Acids Res, 12, 387-395, 1984, available from Genetics Computer Group, Madison, Wisconsin, USA), for example the programs BESTFIT and GAP, may be used to determine the % identity between two polynucleotides and the % identity and the % similarity between two polypeptide sequences. BESTFIT uses the "local homology" algorithm of Smith and Waterman (J Mol Biol, 147,195-197, 1981, Advances in Applied Mathematics, 2, 482-489, 1981) and finds the best single region of similarity between two sequences. BESTFIT is more suited to comparing two polynucleotide or two polypeptide sequences that are dissimilar in length, the program assuming that the shorter sequence represents a portion of the longer. In comparison, GAP

aligns two sequences, finding a "maximum similarity", according to the algorithm of Needleman and Wunsch (J Mol Biol, 48, 443-453, 1970). GAP is more suited to comparing sequences that are approximately the same length and an alignment is expected over the entire length. Preferably, the parameters "Gap Weight" and "Length Weight" used in each program are 50 and 3, for polynucleotide sequences and 12 and 4 for polypeptide sequences, respectively. Preferably, % identities and similarities are determined when the two sequences being compared are optimally aligned.

Other programs for determining identity and/or similarity between sequences are also known in the art, for instance the BLAST family of programs (Altschul S F et al, J Mol Biol, 215, 403-410, 1990, Altschul S F et al, Nucleic Acids Res., 25:389-3402, 1997, available from the National Center for Biotechnology Information (NCBI), Bethesda, Maryland, USA and accessible through the home page of the NCBI at [www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)) and FASTA (Pearson W R, Methods in Enzymology, 183, 63-99, 1990; Pearson W R and Lipman D J, Proc Nat Acad Sci USA, 85, 2444-2448, 1988, available as part of the Wisconsin Sequence Analysis Package).

Preferably, the BLOSUM62 amino acid substitution matrix (Henikoff S and Henikoff J G, Proc. Nat. Acad Sci. USA, 89, 10915-10919, 1992) is used in polypeptide sequence comparisons including where nucleotide sequences are first translated into amino acid sequences before comparison.

Preferably, the program BESTFIT is used to determine the % identity of a query polynucleotide or a polypeptide sequence with respect to a reference polynucleotide or a polypeptide sequence, the query and the reference sequence being optimally aligned and the parameters of the program set at the default value, as hereinbefore described.

"Identity Index" is a measure of sequence relatedness which may be used to compare a candidate sequence (polynucleotide or polypeptide) and a reference sequence. Thus, for instance, a candidate polynucleotide sequence having, for example, an Identity Index of 0.95 compared to a reference polynucleotide sequence is identical to the reference sequence except that the candidate polynucleotide sequence

5 may include on average up to five differences per each 100 nucleotides of the reference sequence. Such differences are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion. These differences may occur at the 5' or 3' terminal positions of the reference polynucleotide sequence or  
10 anywhere between these terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. In other words, to obtain a polynucleotide sequence having an Identity Index of 0.95 compared to a reference polynucleotide sequence, an average of up to 5 in every 100 of the nucleotides of the in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described. The same applies *mutatis mutandis* for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.

15 Similarly, for a polypeptide, a candidate polypeptide sequence having, for example, an Identity Index of 0.95 compared to a reference polypeptide sequence is identical to the reference sequence except that the polypeptide sequence may include an average of up to five differences per each 100 amino acids of the reference sequence. Such differences  
20 are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion. These differences may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between these terminal positions, interspersed either  
25 individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. In other words, to obtain a polypeptide sequence having an Identity Index of 0.95 compared to a reference polypeptide sequence, an average of up to 5 in every 100 of the amino acids in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore  
30 described. The same applies *mutatis mutandis* for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.

The relationship between the number of nucleotide or amino acid differences and the Identity Index may be expressed in the following  
35 equation:

$$n_a \leq x_a - (x_a \cdot I),$$

in which:

$n_a$  is the number of nucleotide or amino acid differences,

$x_a$  is the total number of nucleotides or amino acids in the SEQ ID NO: 2 OR 4, respectively,

5  $I$  is the Identity Index ,

• is the symbol for the multiplication operator, and

in which any non-integer product of  $x_a$  and  $I$  is rounded down to the nearest integer prior to subtracting it from  $x_a$ .

10 "Homolog" is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a reference sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the two sequences as hereinbefore defined. Falling within this generic term are the terms "ortholog", and "paralog". "Ortholog" refers to a polynucleotide or polypeptide that is the functional equivalent of the polynucleotide or polypeptide in another species. "Paralog" refers to a polynucleotide or polypeptide that within the same species which is functionally similar.

15 "Fusion protein" refers to a protein encoded by two, unrelated, fused genes or fragments thereof. Examples have been disclosed in US 5541087, 5726044. In the case of Fc-PDE7b, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for performing the functional expression of Fc-PDE7b, to improve pharmacokinetic properties of such a fusion protein when used for therapy and to generate a dimeric PDE7b. The Fc-PDE7b DNA construct comprises in 5' to 3' direction, a secretion cassette, i.e. a signal sequence that triggers export from a mammalian cell, DNA encoding an immunoglobulin Fc region fragment, as a fusion partner, and a DNA encoding PDE7b. In some uses it would be desirable to be able to alter the intrinsic functional properties (complement binding, Fc-Receptor binding) by mutating the functional Fc sides while leaving the rest of the fusion protein untouched or delete the Fc-part completely after expression.

20

25

30

5 All publications and references, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference in their entirety as if each individual publication or reference were specifically and individually indicated to be incorporated by reference herein as being fully set forth. Any patent application to which this application claims priority is also incorporated by reference herein in its entirety in the manner described above for publications and references.

10 Figure: 1 Expression pattern of PDE 7b

Analysis of the expression of PDE 7b polypeptide mRNA in various human tissues and organs was performed as given in Example 1. The tissues and organs given in Figure 1 are as follows:

- 1 Brain
- 2 Fetal Brain
- 3 Fetal Liver
- 4 Heart
- 5 Kidney
- 6 Liver
- 7 Lung
- 8 Pancreas
- 9 Prostate
- 10 Sceletal Muscle
- 11 Small Intestine
- 12 Spleen
- 13 Testis
- 14 Uterus

15 **Further Examples**

Example 1

20 The tissue distribution of the novel PDE 7b was investigated during a series of experiments: the cDNA encoding the novel PDE 7b was amplified by PCR using primers that reside with the vector and the resulting PCR product was spotted on multiple filters. cDNAs derived from different normal human tissues (as indicated in the chart) was labelled with <sup>33</sup>P and used to hybridize the filters. The filters were counted in a phosphoimager and the resulting count normalized to the

total counts on each filter. Each tissue cDNA was hybridized at least in duplicate.

The novel PDE 7b is found in all tissues analyzed so far at a moderate level with highest values in fetal liver, heart and liver.

**Claims**

1. A polypeptide selected from one of the groups consisting of:
  - (a) a polypeptide encoded by a polynucleotide comprising the sequence of any one of SEQ ID NO:1 or 3
  - 5 (b) a polypeptide comprising a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2 or 4
  - c) a polypeptide having at least 95% identity to the polypeptide sequence of SEQ ID NO: 2 or 4, and
  - d) the polypeptide sequence of SEQ ID NO: 2or 4, and
  - 10 (e) fragments and variants of the polypeptides of any one of (a) to (d).
  
2. The polypeptide of claim 1 comprising the polypeptide sequence of SEQ ID NO: 2 or 4
  
- 15 3. The polypeptide of claim 1 which is the polypeptide sequence of SEQ ID NO: 2 or 4
  
4. A polynucleotide selected from the group consisting of:
  - (a) an polynucleotide comprising a polynucleotide sequence having at least 95% identity to the polynucleotide sequence of SEQ ID NO: 1 or 3,
  - 20 (b) an polynucleotide having at least 95% identity to the polynucleotide of SEQ ID NO: 1or 3,
  - (c) an polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO: 2 or 4,
  - 25 (d) an polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95% identity to the polypeptide \*sequence of SEQ ID NO: 2 or 4,

(e) an polynucleotide with a nucleotide sequence of at least 100 nucleotides obtained by screening a library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or 3, or a fragment thereof having at least 15 nucleotides;

5 (f) a polynucleotide which is the RNA equivalent of a polynucleotide of (a) to (e);

(g) a polynucleotide sequence complementary to said polynucleotide of any one of (a) to (g);

10 (h) any one of (a) to (g); and polynucleotides that are variants and fragments of the polynucleotides of any one of (a) to (g); or that are complementary to polynucleotides over the entire length thereof.

5. An polynucleotide of claim 4 selected from the group consisting of:

(a) a polynucleotide comprising the polynucleotide of SEQ ID NO: 1 or 3

15 (b) the polynucleotide of SEQ ID NO: 1 or 3

(c) (c) a polynucleotide comprising a polynucleotide sequence encoding the polypeptide of SEQ ID NO: 2 or 4, and

(d) a polynucleotide encoding the polypeptide of SEQ ID NO: 2 or 4

20 6. An expression system comprising a polynucleotide capable of producing a polypeptide of any one of claim 1 to 3 when said expression vector is present in a compatible host cell.

25 7. A recombinant host cell comprising the expression vector of claim 6 or a membrane thereof expressing the polypeptide of any one of claims 1 to 3.

8. A process for producing a polypeptide of any one of claim 1 to 3 comprising the step of culturing a host cell of claim 7 under conditions

sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium.

5 9. A fusion protein consisting of the Immunoglobulin Fc-region and any one polypeptide of any one of claim 1-3.

10. An antibody immunospecific for the polypeptide of any one of claims 1 to 3.

10 11. A method for screening to identify compounds that stimulate or inhibit the function or level of the polypeptide of any one of claims 1 to 3 comprising a method selected from the group consisting of:

(a) measuring or, detecting, quantitatively or qualitatively, the binding of a candidate compound to the polypeptide (or to the cells or membranes expressing the polypeptide) or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound;

15 (b) measuring the competition of binding of a candidate compound to the polypeptide (or to the cells or membranes expressing the polypeptide) or a fusion protein thereof in the presence of a labeled competitor;

20 (c) testing whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells or cell membranes expressing the polypeptide;


(d) mixing a candidate compound with a solution containing a polypeptide of any one of claims 1-3, to form a mixture, measuring activity of the polypeptide in the mixture, and comparing the activity of the mixture to a control mixture which contains no candidate compound; or

25 (e) detecting the effect of a candidate compound on the production of mRNA encoding said polypeptide or said polypeptide in cells, using for instance, an ELISA assay, and

(f) producing said compound according to biotechnological or chemical standard techniques.

Fig. 1

Tissue distribution pattern of novel PDE7b



## SEQUENCE LISTING

<110> Merck Patent GmbH  
 5  
 <120> New PDE7B  
 <130> newpd7b  
 10 <140>  
 <141>  
 <160> 4  
 15 <170> PatentIn Ver. 2.1  
 <210> 1  
 <211> 1353  
 <212> DNA  
 20 <213> Homo sapiens  
 <220>  
 <221> CDS  
 <222> (1)..(1353)  
 25  
 <400> 1  
 atg tct tgt tta atg gtt gag agg tgt ggc gaa atc ttg ttt gag aac 48  
 Met Ser Cys Leu Met Val Glu Arg Cys Gly Glu Ile Leu Phe Glu Asn  
 1 5 10 15  
 30 ccc gat cag aat gcc aaa tgt gtt tgc atg ctg gga gat ata cga cta 96  
 Pro Asp Gln Asn Ala Lys Cys Val Cys Met Leu Gly Asp Ile Arg Leu  
 20 25 30  
 35 agg ggt cag acg ggg gtt cgt gct gaa cgc cgt ggc tcc tac cca ttc 144  
 Arg Gly Gln Thr Gly Val Arg Ala Glu Arg Arg Gly Ser Tyr Pro Phe  
 35 40 45  
 40 att gac ttc cgc cta ctt aac agt aca aca tac tca ggg gag att ggc 192  
 Ile Asp Phe Arg Leu Leu Asn Ser Thr Thr Tyr Ser Gly Glu Ile Gly  
 50 55 60  
 acc aag aaa aag gtg aaa aga cta tta agc ttt caa aga tac ttc cat 240  
 Thr Lys Lys Lys Val Lys Arg Leu Leu Ser Phe Gln Arg Tyr Phe His  
 45 65 70 75 80  
 gca tca agg ctg ctt cgt gga att ata cca caa gcc cct ctg cac ctg 288  
 Ala Ser Arg Leu Leu Arg Gly Ile Ile Pro Gln Ala Pro Leu His Leu  
 85 90 95  
 50 ctg gat gaa gac tac ctt gga caa gca agg cat atg ctc tcc aaa gtg 336  
 Leu Asp Glu Asp Tyr Leu Gly Gln Ala Arg His Met Leu Ser Lys Val  
 100 105 110  
 55 gga atg tgg gat ttt gac att ttc ttg ttt gat cgc ttg aca aat gga 384  
 Gly Met Trp Asp Phe Asp Ile Phe Leu Phe Asp Arg Leu Thr Asn Gly  
 115 120 125  
 aac agc ctg gta aca ctg ttg tgc cac ctc ttc aat acc cat gga ctc 432

	Asn	Ser	Leu	Val	Thr	Leu	Leu	Cys	His	Leu	Phe	Asn	Thr	His	Gly	Leu	
		130					135					140					
5	att	cac	cat	ttc	aag	tta	gat	atg	gtg	acc	tta	cac	cga	ttt	tta	gtc	480
	Ile	His	His	Phe	Lys	Leu	Asp	Met	Val	Thr	Leu	His	Arg	Phe	Leu	Val	
	145					150					155					160	
10	atg	gtt	caa	gaa	gat	tac	cac	agc	caa	aac	ccg	tat	cac	aat	gct	gtt	528
	Met	Val	Gln	Glu	Asp	Tyr	His	Ser	Gln	Asn	Pro	Tyr	His	Asn	Ala	Val	
					165					170						175	
15	cac	gca	gcc	gac	gtc	acc	cag	gcc	atg	cac	tgc	tac	ctg	aaa	gag	cca	576
	His	Ala	Ala	Asp	Val	Thr	Gln	Ala	Met	His	Cys	Tyr	Leu	Lys	Glu	Pro	
				180					185						190		
20	aag	ctt	gcc	agc	ttc	ctc	acg	cct	ctg	gac	atc	atg	ctt	gga	ctg	ctg	624
	Lys	Leu	Ala	Ser	Phe	Leu	Thr	Pro	Leu	Asp	Ile	Met	Leu	Gly	Leu	Leu	
			195					200					205				
25	gct	gca	gca	gca	cac	gat	gtg	gac	cac	cca	ggg	gtg	aac	cag	cca	ttt	672
	Ala	Ala	Ala	Ala	His	Asp	Val	Asp	His	Pro	Gly	Val	Asn	Gln	Pro	Phe	
		210					215					220					
30	ttg	ata	aaa	act	aac	cac	cat	ctt	gca	aac	cta	tat	cag	aat	atg	tct	720
	Leu	Ile	Lys	Thr	Asn	His	His	Leu	Ala	Asn	Leu	Tyr	Gln	Asn	Met	Ser	
	225				230					235						240	
35	gtg	ctg	gag	aat	cat	cac	tgg	cga	tct	aca	att	ggc	atg	ctt	cga	gaa	768
	Val	Leu	Glu	Asn	His	His	Trp	Arg	Ser	Thr	Ile	Gly	Met	Leu	Arg	Glu	
				245					250						255		
40	tca	agg	ctt	ctt	gct	cat	ttg	cca	aag	gaa	atg	aca	cag	gat	att	gaa	816
	Ser	Arg	Leu	Leu	Ala	His	Leu	Pro	Lys	Glu	Met	Thr	Gln	Asp	Ile	Glu	
				260					265					270			
45	cag	cag	ctg	ggc	tcc	ttg	atc	ttg	gca	aca	gac	atc	aac	agg	cag	aat	864
	Gln	Gln	Leu	Gly	Ser	Leu	Ile	Leu	Ala	Thr	Asp	Ile	Asn	Arg	Gln	Asn	
			275					280					285				
50	gaa	ttt	ttg	acc	aga	ttg	aaa	gct	cac	ctc	cac	aat	aaa	gac	tta	aga	912
	Glu	Phe	Leu	Thr	Arg	Leu	Lys	Ala	His	Leu	His	Asn	Lys	Asp	Leu	Arg	
		290				295						300					
55	ctg	gag	gat	gca	cag	gac	agg	cac	ttt	atg	ctt	cag	atc	gcc	ttg	aag	960
	Leu	Glu	Asp	Ala	Gln	Asp	Arg	His	Phe	Met	Leu	Gln	Ile	Ala	Leu	Lys	
	305					310					315				320		
60	tgt	gct	gac	att	tgc	aat	cct	tgt	aga	atc	tgg	gag	atg	agc	aag	cag	1008
	Cys	Ala	Asp	Ile	Cys	Asn	Pro	Cys	Arg	Ile	Trp	Glu	Met	Ser	Lys	Gln	
					325				330						335		
65	tgg	agt	gaa	agg	gtc	tgt	gaa	gaa	ttc	tac	agg	caa	ggg	gaa	ctt	gaa	1056
	Trp	Ser	Glu	Arg	Val	Cys	Glu	Glu	Phe	Tyr	Arg	Gln	Gly	Glu	Leu	Glu	
				340					345					350			
70	cag	aaa	ttt	gaa	ctg	gaa	atc	agt	cct	ctt	tgt	aat	caa	cag	aaa	gat	1104
	Gln	Lys	Phe	Glu	Leu	Glu	Ile	Ser	Pro	Leu	Cys	Asn	Gln	Gln	Lys	Asp	
			355					360					365				
75	tcc	atc	cct	agt	ata	caa	att	ggg	ttc	atg	agc	tac	atc	gtg	gag	ccg	1152
	Ser	Ile	Pro	Ser	Ile	Gln	Ile	Gly	Phe	Met	Ser	Tyr	Ile	Val	Glu	Pro	

	370		375		380		
	ctc ttc cgg gaa tgg gcc cat ttc acg ggt aac agc acc ctg tcg gag					1200	
	Leu Phe Arg Glu Trp Ala His Phe Thr Gly Asn Ser Thr Leu Ser Glu						
5	385		390		395		400
	aac atg ctg ggc cac ctc gca cac aac aag gcc cag tgg aag agc ctg					1248	
	Asn Met Leu Gly His Leu Ala His Asn Lys Ala Gln Trp Lys Ser Leu						
10		405		410			415
	ttg ccc agg cag cac aga agc agg ggc agc agt ggc agc ggg cct gac					1296	
	Leu Pro Arg Gln His Arg Ser Arg Gly Ser Ser Gly Ser Gly Pro Asp						
		420		425			430
15	cac gac cac gca ggc caa ggg act gag agc gag gag cag gaa ggc gac					1344	
	His Asp His Ala Gly Gln Gly Thr Glu Ser Glu Glu Gln Glu Gly Asp						
		435		440			445
20	agc ccc tag						1353
	Ser Pro						
	450						
25	<210> 2						
	<211> 450						
	<212> PRT						
	<213> Homo sapiens						
30	<400> 2						
	Met Ser Cys Leu Met Val Glu Arg Cys Gly Glu Ile Leu Phe Glu Asn						
	1 5 10 15						
	Pro Asp Gln Asn Ala Lys Cys Val Cys Met Leu Gly Asp Ile Arg Leu						
	20 25 30						
35	Arg Gly Gln Thr Gly Val Arg Ala Glu Arg Arg Gly Ser Tyr Pro Phe						
	35 40 45						
	Ile Asp Phe Arg Leu Leu Asn Ser Thr Thr Tyr Ser Gly Glu Ile Gly						
	50 55 60						
	Thr Lys Lys Lys Val Lys Arg Leu Leu Ser Phe Gln Arg Tyr Phe His						
	65 70 75 80						
40	Ala Ser Arg Leu Leu Arg Gly Ile Ile Pro Gln Ala Pro Leu His Leu						
	85 90 95						
	Leu Asp Glu Asp Tyr Leu Gly Gln Ala Arg His Met Leu Ser Lys Val						
	100 105 110						
45	Gly Met Trp Asp Phe Asp Ile Phe Leu Phe Asp Arg Leu Thr Asn Gly						
	115 120 125						
	Asn Ser Leu Val Thr Leu Leu Cys His Leu Phe Asn Thr His Gly Leu						
	130 135 140						
	Ile His His Phe Lys Leu Asp Met Val Thr Leu His Arg Phe Leu Val						
	145 150 155 160						
50	Met Val Gln Glu Asp Tyr His Ser Gln Asn Pro Tyr His Asn Ala Val						
	165 170 175						
	His Ala Ala Asp Val Thr Gln Ala Met His Cys Tyr Leu Lys Glu Pro						
	180 185 190						
55	Lys Leu Ala Ser Phe Leu Thr Pro Leu Asp Ile Met Leu Gly Leu Leu						
	195 200 205						
	Ala Ala Ala Ala His Asp Val Asp His Pro Gly Val Asn Gln Pro Phe						
	210 215 220						
	Leu Ile Lys Thr Asn His His Leu Ala Asn Leu Tyr Gln Asn Met Ser						
	225 230 235 240						
60	Val Leu Glu Asn His His Trp Arg Ser Thr Ile Gly Met Leu Arg Glu						
	245 250 255						

Ser Arg Leu Leu Ala His Leu Pro Lys Glu Met Thr Gln Asp Ile Glu  
 260 265 270  
 Gln Gln Leu Gly Ser Leu Ile Leu Ala Thr Asp Ile Asn Arg Gln Asn  
 275 280 285  
 5 Glu Phe Leu Thr Arg Leu Lys Ala His Leu His Asn Lys Asp Leu Arg  
 290 295 300  
 Leu Glu Asp Ala Gln Asp Arg His Phe Met Leu Gln Ile Ala Leu Lys  
 305 310 315 320  
 10 Cys Ala Asp Ile Cys Asn Pro Cys Arg Ile Trp Glu Met Ser Lys Gln  
 325 330 335  
 Trp Ser Glu Arg Val Cys Glu Glu Phe Tyr Arg Gln Gly Glu Leu Glu  
 340 345 350  
 Gln Lys Phe Glu Leu Glu Ile Ser Pro Leu Cys Asn Gln Gln Lys Asp  
 355 360 365  
 15 Ser Ile Pro Ser Ile Gln Ile Gly Phe Met Ser Tyr Ile Val Glu Pro  
 370 375 380  
 Leu Phe Arg Glu Trp Ala His Phe Thr Gly Asn Ser Thr Leu Ser Glu  
 385 390 395 400  
 20 Asn Met Leu Gly His Leu Ala His Asn Lys Ala Gln Trp Lys Ser Leu  
 405 410 415  
 Leu Pro Arg Gln His Arg Ser Arg Gly Ser Ser Gly Ser Gly Pro Asp  
 420 425 430  
 His Asp His Ala Gly Gln Gly Thr Glu Ser Glu Glu Gln Glu Gly Asp  
 435 440 445  
 25 Ser Pro  
 450

30 <210> 3  
 <211> 1175  
 <212> DNA  
 <213> Homo sapiens

35 <220>  
 <221> CDS  
 <222> (3)..(1175)

<400> 3

40 gg cac gag agg aga gag aga gag aga gag cgc cta ctt aac agt aca 47  
 His Glu Arg Arg Glu Arg Glu Arg Glu Arg Leu Leu Asn Ser Thr  
 1 5 10 15

aca tac tca ggg gag att ggc acc aag aaa aag gtg aaa aga cta tta 95  
 45 Thr Tyr Ser Gly Glu Ile Gly Thr Lys Lys Lys Val Lys Arg Leu Leu  
 20 25 30

agc ttt caa aga tac ttc cat gca tca agg ctg ctt cgt gga att ata 143  
 50 Ser Phe Gln Arg Tyr Phe His Ala Ser Arg Leu Leu Arg Gly Ile Ile  
 35 40 45

cca caa gcc cct ctg cac ctg ctg gat gaa gac tac ctt gga caa gca 191  
 55 Pro Gln Ala Pro Leu His Leu Leu Asp Glu Asp Tyr Leu Gly Gln Ala  
 50 55 60

agg cat atg ctc tcc aaa gtg gga atg tgg gat ttt gac att ttc ttg 239  
 Arg His Met Leu Ser Lys Val Gly Met Trp Asp Phe Asp Ile Phe Leu  
 65 70 75

60 ttt gat cgc ttg aca aat gga aac agc ctg gta aca ctg ttg tgc cac 287  
 Phe Asp Arg Leu Thr Asn Gly Asn Ser Leu Val Thr Leu Leu Cys His

	80		85		90		95	
5	ctc ttc aat acc cat	gga ctc att cac cat	ttc aag tta gat atg gtg	335	Leu Phe Asn Thr His	Gly Leu Ile His His	Phe Lys Leu Asp Met Val	
		100		105			110	
10	acc tta cac cga ttt tta	gtc atg gtt caa gaa gat tac cac agc caa	383	Thr Leu His Arg Phe	Leu Val Met Val Gln Glu	Asp Tyr His Ser Gln		
		115		120			125	
15	aac ccg tat cac aat gct	gtt cac gca gcc gac gtc acc cag gcc atg	431	Asn Pro Tyr His Asn	Ala Val His Ala Ala	Asp Val Thr Gln Ala Met		
		130		135			140	
20	cac tgc tac ctg aaa gar	cca aag ctt gcc agc ttc ctc acg cct ctg	479	His Cys Tyr Leu Lys	Glu Pro Lys Leu Ala	Ser Phe Leu Thr Pro Leu		
		145		150			155	
25	gac atc atg ctt gga ctg	ctg gct gca gca gca cac gat gtg gac cac	527	Asp Ile Met Leu Gly	Leu Leu Ala Ala Ala	Ala His Asp Val Asp His		
		160		165			170	175
30	cca ggg gtg aac cag cca	ttt ttg ata aaa act aac cmc cat ctt gca	575	Pro Gly Val Asn Gln	Pro Phe Leu Ile Lys	Thr Asn Xaa His Leu Ala		
		180		185			190	
35	aac cta tat cag aat atg	tct gtg ctg gag aat cat cac tgg cga tct	623	Asn Leu Tyr Gln Asn	Met Ser Val Leu Glu	Asn His His Trp Arg Ser		
		195		200			205	
40	aca att ggc atg ctt cga	gaa tca agg ctt ctt gct cat ttg cca aag	671	Thr Ile Gly Met Leu	Arg Glu Ser Arg Leu	Leu Ala His Leu Pro Lys		
		210		215			220	
45	gaa atg aca cag gat att	gaa cag cag ctg ggc tcc ttg atc ttg gca	719	Glu Met Thr Gln Asp	Ile Glu Gln Gln Leu	Gly Ser Leu Ile Leu Ala		
		225		230			235	
50	aca gac atc aac agg cag	aat gaa ttt ttg acc aga ttg aaa gct cac	767	Thr Asp Ile Asn Arg	Gln Asn Glu Phe Leu	Thr Arg Leu Lys Ala His		
		240		245			250	255
55	ctc cac aat aaa gac tta	aga ctg gag gat gca cag gac agg cac ttt	815	Leu His Asn Lys Asp	Leu Arg Leu Glu Asp	Ala Gln Asp Arg His Phe		
		260		265			270	
60	atg ctt cag atc gcc ttg	aag tgt gct gac att tgc aat cct tgt aga	863	Met Leu Gln Ile Ala	Leu Lys Cys Ala Asp	Ile Cys Asn Pro Cys Arg		
		275		280			285	
65	atc tgg gag atg agc aag	cag tgg agt gaa agg gtc tgt gaa gaa ttc	911	Ile Trp Glu Met Ser	Lys Gln Trp Ser Glu	Arg Val Cys Glu Glu Phe		
		290		295			300	
70	tac agg caa ggt gaa ctt	gaa cag aaa ttt gga ctg gaa atc agt cct	959	Tyr Arg Gln Gly Glu	Leu Glu Gln Lys Phe	Gly Leu Glu Ile Ser Pro		
		305		310			315	
75	ctt tgt aat caa cag aaa	gat tcc atc cct agt ata caa att ggt ttc	1007	Leu Cys Asn Gln Gln	Lys Asp Ser Ile Pro	Ser Ile Gln Ile Gly Phe		
		320		325			330	335

atg agc tac atc gtg gag ccc gct ctt ccg gga atg gcc cat ttc acg 1055  
 Met Ser Tyr Ile Val Glu Pro Ala Leu Pro Gly Met Ala His Phe Thr  
 340 345 350  
 5  
 ggt aac agc acc ctg cag aga aca tgc tgg gcc acc ttc gca cac aac 1103  
 Gly Asn Ser Thr Leu Gln Arg Thr Cys Trp Ala Thr Phe Ala His Asn  
 355 360 365  
 10 aag ggc cag tgg aag agc ctg ttg cca agc agt aca gaa gca ggg gct 1151  
 Lys Gly Gln Trp Lys Ser Leu Leu Pro Ser Ser Thr Glu Ala Gly Ala  
 370 375 380  
 15 gca ttg gca gnn ggc ctt gac cac 1175  
 Ala Leu Ala Xaa Gly Leu Asp His  
 385 390  
 <210> 4  
 20 <211> 391  
 <212> PRT  
 <213> Homo sapiens  
 <400> 4  
 25 His Glu Arg Arg Glu Arg Glu Arg Glu Arg Leu Leu Asn Ser Thr Thr  
 1 5 10 15  
 Tyr Ser Gly Glu Ile Gly Thr Lys Lys Lys Val Lys Arg Leu Leu Ser  
 20 25 30  
 30 Phe Gln Arg Tyr Phe His Ala Ser Arg Leu Leu Arg Gly Ile Ile Pro  
 35 40 45  
 35 Gln Ala Pro Leu His Leu Leu Asp Glu Asp Tyr Leu Gly Gln Ala Arg  
 50 55 60  
 His Met Leu Ser Lys Val Gly Met Trp Asp Phe Asp Ile Phe Leu Phe  
 65 70 75 80  
 40 Asp Arg Leu Thr Asn Gly Asn Ser Leu Val Thr Leu Leu Cys His Leu  
 85 90 95  
 Phe Asn Thr His Gly Leu Ile His His Phe Lys Leu Asp Met Val Thr  
 100 105 110  
 45 Leu His Arg Phe Leu Val Met Val Gln Glu Asp Tyr His Ser Gln Asn  
 115 120 125  
 50 Pro Tyr His Asn Ala Val His Ala Ala Asp Val Thr Gln Ala Met His  
 130 135 140  
 Cys Tyr Leu Lys Glu Pro Lys Leu Ala Ser Phe Leu Thr Pro Leu Asp  
 145 150 155 160  
 55 Ile Met Leu Gly Leu Leu Ala Ala Ala Ala His Asp Val Asp His Pro  
 165 170 175  
 Gly Val Asn Gln Pro Phe Leu Ile Lys Thr Asn Xaa His Leu Ala Asn  
 180 185 190  
 60 Leu Tyr Gln Asn Met Ser Val Leu Glu Asn His His Trp Arg Ser Thr

